SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation
He describes how he believes the TL1A compares to others in the field, other programs in the company's innovation pipeline, and the current status of market uptake for biosimilars in Europe and the United States.